Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2007-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two
FDA approved drugs in combination versus one FDA approved drug in subjects with advanced
non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or
HYCAMTIN.